Please ensure Javascript is enabled for purposes of website accessibility

BioLife Solutions to Buy SciSafe in $30 Million Deal

By Eric Volkman – Sep 21, 2020 at 2:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's a classic vertical integration move.

BioLife Solutions (BLFS -2.12%) is starting the week with a bang. On Monday morning, the company announced it has signed a definitive agreement to purchase privately held SciSafe. The price is $30 million, which will be paid half in cash and half in newly issued BioLife common shares.

SciSafe's current investors also will be eligible for up to 626,000 additional shares if the assets from the business hit certain annual revenue milestones. The incentive plan will be in force for a period of four years, but BioLife did not provide any further details about the milestones to be hit. At BioLife's current share price, 626,000 shares would be worth just under $17 million.

In the wake of the announcement, BioLife's stock was trading down marginally, yet still outperforming the top equity market indexes.

Gloved hand gripping beaker filled with U.S. currency, with currency also underneath the beaker.

Image source: Getty Images.

Investors might feel that the company, which specializes in products that are used in a fairly wide range of cell and gene therapies, is buying quite a complementary asset. SciSafe provides biological and pharmaceutical storage targeted at the same pool of clients as its soon-to-be owner, in addition to top pharmaceutical companies.

BioLife CEO Mike Rice said that the deal "enables BioLife to offer even more value to our cell and gene therapy customers through an established business with an excellent reputation, marquee customers and seasoned team."

"Through SciSafe, we are accelerating profitable growth by expanding into the high growth biostorage segment with a robust quality system, a scalable business model and strong financial performance," he added.

BioLife said it expects the absorption of SciSafe will contribute $1.8 million to its fourth-quarter revenue; that figure should tally $9 million for the entirety of 2021. SciSafe is anticipated to be accretive to non-GAAP (adjusted) net income beginning next year.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

BioLife Solutions Stock Quote
BioLife Solutions
$18.50 (-2.12%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.